London, UK: 12 September 2006 Data to be presented today show that combining Antisoma's AS1404 with the anti-EGF-receptor antibody Erbitux™ (cetuximab) produces a synergistic reduction in the growth of lung cancer xenografts. This adds another targeted therapy to the list of agents with which AS1404 has been successfully combined.
